ALX Oncology Holdings Inc. (ALXO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.2 |
| Open | 2.2 |
| Day High | 2.22 |
| Day Low | 2.05 |
| 52-Week High | 2.66 |
| 52-Week Low | 0.41 |
| Volume | 984,751 |
| Average Volume | 1.39M |
| Market Cap | 278.55M |
| PE | -1.39 |
| EPS | -1.49 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 1.71 |
| Change | -0.13 |
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
GlobeNewswire Inc.
Feb 19, 2026 1:33 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
GlobeNewswire Inc.
Feb 19, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l
ALX Oncology Announces Pricing of Underwritten Offering
GlobeNewswire Inc.
Jan 30, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l